[Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
Bodet
Domingo
D
Bartralot
Ramón
R
Mollet
Jordi
J
Heras
Cristina
C
García-Patos
Vicente
V
D017486:Acneiform Eruptions / Q000139:chemically induced*; D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000473:pathology; D004198:Disease Susceptibility; D003875:Drug Eruptions / Q000209:etiology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000077156:Gefitinib; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*; D013207:Staphylococcal Skin Infections / Q000209:etiology*; D015163:Superinfection / Q000209:etiology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D011799:Quinazolines; D066246:ErbB Receptors; D000068818:Cetuximab; D000077156:Gefitinib